Flavopiridol inhibits cellular processes essential to replication of HIV
16 September 2000. Related: Antiretrovirals.
2000
Abbott expands early-access program for ABT-378/r (Kaletra)
16 September 2000. Related: Antiretrovirals.
Roche and Trimeris announce intention to manufacture commercial supplies of anti-HIV fusion inhibitor T-20
16 September 2000. Related: Antiretrovirals.
PRO-542 shows efficacy in trial
16 September 2000. Related: Antiretrovirals.
Immunorestitution disease
16 September 2000. Related: Other news.
Prevalence of psoriatic arthritis increasing among HIV-positive black Zambians
16 September 2000. Related: Coinfections and complications.
HAART: enough to make your hair curl?
16 September 2000. Related: Side effects.
Loans to buy AIDS drugs are rejected by Africans
16 September 2000. Related: Treatment access.
Volume 1 Number 6 September 2000 PDF
1 September 2000. Related: PDFs.
Severe Hypersensitivity Reactions following reintroduction with Ziagen (abacavir sulphate)
16 August 2000. Related: Treatment alerts.
XIII International AIDS Conference, Durban, South Africa, 9-14th July 2000
16 August 2000. Related: Conference reports.
Mother-to-child transmission, maternal health and women’s access to care
16 August 2000. Related: Conference reports, Pregnancy.
The M in MTCT: questions about HIV-positive mothers
16 August 2000. Related: Conference reports, Pregnancy.
First report of ABT-378/r use in children
16 August 2000. Related: Conference reports, Paediatric care.
Nelfinavir doses should be increased in infants less than 3 months
16 August 2000. Related: Conference reports, Paediatric care.
Metabolic and lipodystropy issues: confusion continues to reign
16 August 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?
16 August 2000. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Commentary on STI talk, early entry inhibitor research, increase in viral replication seen in isolates in presence of NNRTIs
16 August 2000. Related: Conference reports.
New developments in affordable antiretroviral therapy: intermittent treatment
16 August 2000. Related: Conference reports, Treatment strategies.
Cannabinoids effect on HIV-1 viral load and appetite
16 August 2000. Related: Conference reports.
IL-2 without HAART may delay need for antiretroviral treatment
16 August 2000. Related: Conference reports.
New potential dual NNRTI-based combinations
16 August 2000. Related: Conference reports, Antiretrovirals.
Once-daily protease-based regimens
16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.
Mitochondrial DNA (mtDNA) damage in semen as surrogate marker for nucleoside analogue toxicity
16 August 2000. Related: Conference reports, Side effects.
Antiretrovirals and fertility – implications for couples looking to conceive
16 August 2000. Related: Conference reports.
Incidence of adverse events at 4 weeks correlates with adherence and virologic failure at 4 months
16 August 2000. Related: Conference reports, Side effects.
Prednisone and nevirapine rash
16 August 2000. Related: Conference reports, Side effects.
The prevalence of hypogonadism in HIV positive patients receiving HAART
16 August 2000. Related: Conference reports, Other news.
Human papilloma virus and HIV
16 August 2000. Related: Conference reports, Coinfections and complications.
$1bn drug deal creates debt for “tomorrow’s AIDS orphans”
16 August 2000. Related: Treatment access, Other news.
Evaluating structured treatment interruptions: rationale, experience, potential risks and benefits
16 August 2000. Related: On the web.
Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors
16 August 2000. Related: Basic science and immunology.
European drug approvals: amprenavir, ddI EC, Trizivr and Kaletra
16 August 2000. Related: Antiretrovirals.
Volume 1 Number 5 August 2000 PDF
1 August 2000. Related: PDFs.
4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain
16 July 2000. Related: Conference reports.
Tenofovir (PMPA), defining cross-resistance profiles
16 July 2000. Related: Conference reports, Drug resistance.
DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing
16 July 2000. Related: Conference reports, Antiretrovirals.
Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
Hydroxyurea is active in vitro against multidrug-resistant HIV
16 July 2000. Related: Conference reports, Drug resistance.
ABT-378/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients
16 July 2000. Related: Conference reports, Drug resistance.
Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification
16 July 2000. Related: Conference reports, Antiretrovirals.
Ritonavir/saquinavir combination: effect of ritonavir dosage
16 July 2000. Related: Conference reports, Antiretrovirals.
What is the significance of blips in viral load?
16 July 2000. Related: Conference reports, Treatment strategies.
Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001
16 July 2000. Related: Conference reports, Drug resistance.
A prospective study of strategic treatment interruptions in patients with chronic HIV-infection
16 July 2000. Related: Conference reports.
Added value of hydroxyurea or IL-2 to STIs remains uncertain
16 July 2000. Related: Conference reports.
Continued benefits from protease inhibitor based therapy despite virological failure
16 July 2000. Related: Conference reports, Drug resistance.
Do resistance mutations disappear off therapy?
16 July 2000. Related: Conference reports, Drug resistance.
Selection of PI mutations during slow decay of VL and resistance after PI failure
16 July 2000. Related: Conference reports, Drug resistance.
Thymidine analogues mutations (TAMS) and other NA-related resistance mutations
16 July 2000. Related: Conference reports, Drug resistance.
Nevirapine vs efavirenz: the SENC trial
16 July 2000. Related: Conference reports, Antiretrovirals.
A warning on simplification strategies: not suitable for all
16 July 2000. Related: Conference reports.
Prophylaxis and treatment of malaria in the presence of HIV protease inhibitor therapy
16 July 2000. Related: On the web.
The 4th International AIDS Malignancy Conference
16 July 2000. Related: On the web.
Accelerated replicative senescence of the peripheral immune system induced by HIV infection
16 July 2000. Related: Basic science and immunology.
Hit HIV-1 hard, but only when necessary
16 July 2000. Related: Other news.
Gastrostomy tube (G-tube) insertion for improvement of adherence to HAART in pediatric patients with HIV
16 July 2000. Related: Paediatric care.
Study of amino acid methionine for treatment of myelopathy
16 July 2000. Related: Side effects.
3rd report of patient whose NRTI-associated lactic acidosis responded to riboflavin (vitamin B2)
16 July 2000. Related: Side effects.
Immune response may persist after emergence of protease inhibitor-resistant HIV
16 July 2000. Related: Drug resistance.
NIH suspends enrolment in Remune study
16 July 2000. Related: Vaccines and microbicides.
Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily
16 July 2000. Related: Antiretrovirals.
Volume 1 Number 4 July 2000 PDF
1 July 2000. Related: PDFs.
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
16 June 2000. Related: Conference reports.
Obiturary: Kiyoshi Kuromiya, 1943-2000
15 June 2000. Related: Other news.